UY39582A - Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov- 2 y/o la prevención de la infección por coronavirus relacionada con el sarscov- 2 - Google Patents

Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov- 2 y/o la prevención de la infección por coronavirus relacionada con el sarscov- 2

Info

Publication number
UY39582A
UY39582A UY0001039582A UY39582A UY39582A UY 39582 A UY39582 A UY 39582A UY 0001039582 A UY0001039582 A UY 0001039582A UY 39582 A UY39582 A UY 39582A UY 39582 A UY39582 A UY 39582A
Authority
UY
Uruguay
Prior art keywords
sarscov
induction
prevention
aav5
cov
Prior art date
Application number
UY0001039582A
Other languages
English (en)
Inventor
Pavel Mikhailovich Gershovich
Alexander Vladimirovich Prokofyev
Anna Nikolaevna Strelkova
Natalia Aleksandrovna Spirina
Tatiana Evgenievna Shugaeva
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of UY39582A publication Critical patent/UY39582A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invención refiere a un dominio de unión a receptor recombinante aislado de la glicoproteína S (RBD-S) de SARS-CoV-2, a un ácido nucleico que codifica RBD-S de SARS-CoV-2, a un casete de expresión y un vector basado en el mismo, a un virus basado en AAV5 recombinante (virus adenoasociado serotipo 5) para la inducción de inmunidad específica al SARS-CoV-2 y / o la prevención de dicha infección, a un AAV5 - vacuna basada en la inducción de inmunidad específica al SARS-CoV-2 y / o prevención de la infección por coronavirus relacionada con el SARS-CoV-2.
UY0001039582A 2020-12-21 2021-12-21 Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov- 2 y/o la prevención de la infección por coronavirus relacionada con el sarscov- 2 UY39582A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020142220A RU2760301C1 (ru) 2020-12-21 2020-12-21 Вакцина на основе AAV5 для индукции специфического иммунитета к вирусу SARS-CoV-2 и/или профилактики коронавирусной инфекции, вызванной SARS-CoV-2

Publications (1)

Publication Number Publication Date
UY39582A true UY39582A (es) 2022-05-31

Family

ID=78719331

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039582A UY39582A (es) 2020-12-21 2021-12-21 Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov- 2 y/o la prevención de la infección por coronavirus relacionada con el sarscov- 2

Country Status (4)

Country Link
AR (1) AR124461A1 (es)
RU (1) RU2760301C1 (es)
UY (1) UY39582A (es)
WO (1) WO2022139631A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR129552A1 (es) * 2022-06-10 2024-09-04 Joint Stock Company “Biocad” Ácido nucleico con actividad promotora y uso del mismo
CN118307648A (zh) * 2023-01-09 2024-07-09 广东克冠达医药科技有限公司 腺相关病毒衣壳蛋白衍生多肽及其用途
CN117511968B (zh) * 2023-11-06 2024-07-05 军事科学院军事医学研究院军事兽医研究所 表达SARS-CoV-2的S、E和M蛋白的重组金丝雀痘病毒及其构建方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112023035A (zh) * 2020-04-07 2020-12-04 中国医学科学院医学生物学研究所 一种以SARS-CoV-2病毒S蛋白RBD区为抗原的纳米疫苗及其制备
RU2723008C9 (ru) * 2020-05-19 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Способ получения штамма клеток яичника китайского хомячка, продуцента рекомбинантного белка RBD вируса SARS-CoV-2, штамм клеток яичника китайского хомячка, продуцент рекомбинантного белка RBD вируса SARS-CoV-2, способ получения рекомбинантного белка RBD вируса SARS-CoV-2, тест-система для иммуноферментного анализа сыворотки или плазмы крови человека и ее применение
CN111560354B (zh) * 2020-05-22 2022-07-19 中国人民解放军总医院第五医学中心 重组新型冠状病毒及其制备方法和应用
RU2733832C1 (ru) * 2020-07-28 2020-10-07 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Искусственный ген Stbl_RBD_TrM_SC2, кодирующий бицистронную структуру, образованную последовательностями рецепторсвязывающего домена гликопротеина S коронавируса SARS-CoV-2, трансмембранного региона, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_TrM_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_TrM_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2

Also Published As

Publication number Publication date
WO2022139631A1 (en) 2022-06-30
RU2760301C1 (ru) 2021-11-23
AR124461A1 (es) 2023-03-29

Similar Documents

Publication Publication Date Title
UY39582A (es) Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov- 2 y/o la prevención de la infección por coronavirus relacionada con el sarscov- 2
UY39396A (es) Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov-2 y/o la prevención de la infección por coronavirus relacionada con el sarscov-2
BR112022009895A2 (pt) Construtos de terapia de gene de microdistrofina e usos dos mesmos
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
CY1119052T1 (el) Νεες φαρμακοτεχνικες μορφες εμβολιου που περιλαμβανουν ανοσοενισχυτικα που περιεχουν σαπωνινη
PE20181168A1 (es) VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
BR112018011975A2 (pt) composições úteis no tratamento de atrofia muscular espinhal
BR112022016346A2 (pt) Vacina ncov-2019 (sars-cov-2)
BR112022014884A2 (pt) Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave
ZA202204373B (en) Development of a novel live attenuated african swine fever vaccine based in the deletion of gene i177l
EA201170812A1 (ru) Способы и композиции для применения вакцины против кокцидиоза
MX2021012311A (es) Variantes de capsides de aav para liberacion intravitrea.
BR112012031211A2 (pt) métodos e vacina para reduzir a infecção causada pelo campylobacter
BR112022016891A2 (pt) Vacina contra a infecção por vírus da peste suína africana
BRPI0920622A8 (pt) vacina contra o vírus da doença equina africana
CO2017001614A2 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
BR112018068890A2 (pt) dna polimerases marinhas
MX2022001028A (es) Vacuna de la fiebre porcina africana.
BR112022016604A2 (pt) Compostos para uso em infecções virais
MX9304349A (es) Vacuna antirrabica no virulenta.
MX2022015489A (es) Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
ATE493146T1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
BR112022022263A2 (pt) Tratamento de infecções virais
BR112022024911A2 (pt) Materiais e métodos para inibir uma infecção viral, incluindo uma infecção por coronavírus